Skip to main content

A beating Heart-on-Chip for pre-clinical early detection of drugs cardiac safety

Descripción del proyecto

A revolutionary organ on a chip will deliver drug toxicity results in a heartbeat

Drug development is a time-consuming and expensive process involving, among other things, testing for potential unanticipated side effects. Many safety-related drug withdrawals are due to cardiotoxicity. Given the potentially catastrophic consequences of cardiac side effects, evaluating cardiac safety is critical yet remains a major hurdle in drug development. As the pharmaceutical industry seeks alternatives to animal testing, the Italian SME BiomimX has a powerful solution. Integrating 3D cell culture and mechanical stimulation, the company has developed a beating heart on a chip able to respond to drugs much as a human heart would do for rapid toxicity screening very early in the drug pipeline. The EU-funded uHeart project is laying the groundwork to make it commercially available.

Ámbito científico

  • /ciencias sociales/economía y empresa/gestión y empresas/comercio
  • /ciencias médicas y de la salud/medicina básica/farmacología y farmacia/seguridad de los medicamentos

Convocatoria de propuestas

H2020-SMEInst-2018-2020-1
Consulte otros proyectos de esta convocatoria

Régimen de financiación

SME-1 - SME instrument phase 1
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinador

BIOMIMX SRL
Dirección
Via Giovanni Durando 38/A
20158 Milano
Italia
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Aportación de la UE
€ 50 000